ALR Technologies Inc. (“ALRT”) Launches ALRT Diabetes Solution in Private Practice Physician Clinics across Singapore
ALRT Partners with Bionime Corporation to Offer Comprehensive Diabetes Solution at Lower Cost Than Test Supplies Alone Available in Pharmacy Chains
ALRT Diabetes Solution Complements President Trump’s Initiative to Lower Insulin Costs and Drive Better Diabetes Care
ALRT Diabetes Solution will transform lower insulin costs into improved patient outcomes
ALR Technologies Partners with Centrus Health Clinics to Conduct a Clinical Pilot
ALRT will demonstrate proof of its remote diabetes patient management concept in partnership with Clinics of Centrus Health Kansas City
ALR Technologies Inc. Announces Commencement of OTCQB Trading
ALRT has been approved to upgrade the trading of its common stock to the OTCQB Venture Market
ALRT Announces their ALRT Diabetes Solution Provides Telehealth Service Opportunities for Physicians and their Patients
The Coronavirus (COVID-19) pandemic highlights the need for and benefits of Telehealth.
ALRT Announces Corporate Updates
ALRT has applied to OTC Markets to upgrade the trading of its common stock to the OTCQB Venture Market and has had its common stock approved for DWAC FAST
ALRT Partners with Singapore General Hospital to Conduct a Clinical Pilot
ALRT has signed an agreement with Singapore General Hospital to jointly undertake a novel remote diabetes management pilot to prove the efficacy of the ALRT Diabetes Solution in insulin-treated diabetes patients.
ALRT Creates Algorithm to Support Therapy Advancement for Non-Insulin Dependent (NID) Diabetes Patients
ALRT has created an algorithm for advancing medication therapies for patients with non-insulin dependent type 2 diabetes mellitus. The algorithm assists prescribers in making evidence-based medication therapy selections in accordance with the latest clinical practice guidelines set forth by the American Diabetes Association.
ALR Technologies to Integrate with CGM Platforms
ALRT Diabetes Solution is adding support for continuous glucose monitoring (CGM) systems to the ALRT diabetes management platform. There are currently three commercially available CGM devices: the Dexcom G6® (Dexcom, Inc.), the Freestyle Libre (Abbott Laboratories), and the Guardian™ Connect (Medtronic, Inc.).
ALRT Aims for Dramatic Improvements in the Standard of Care For Diabetes
The first-line approach to treating newly diagnosed diabetes is to concentrate on self-management through medication and lifestyle. This is successful when patients adhere to care plans. When self-management does not stop the progression of the disease, the focus of the treatment plan has to switch to optimizing medication using diabetes technology. The clinician needs to be fully engaged in timely intensification when results indicate that it is needed.
ALR Technologies and IDEAS DWC LLC to Market the ALRT Diabetes Solution In the Middle East and North Africa
ALRT’s comprehensive diabetes management system could improve outcomes and provide diagnostic tools for diabetes therapies in one of the world’s most critical diabetes markets
ALR Technologies (ALRT) and Aspire Cerebro Agree to Co-Market the ALRT Diabetes Solution In India
ALRT and Aspire Cerebro will collaborate to market ALRT’s comprehensive diabetes management system to Indian pharmaceutical companies and help improve diabetes management.
ALRT Announces Launch of the Integrated ALRT Diabetes Solution
The Integrated Solution will include **ALRT Diabetes Solution** software, blood glucose test supplies and diabetes management administered by Centers of Excellence for Diabetes Care
ALR Technologies Announces That Its ALRT Diabetes Solution Has Been Developed To An Enterprise-Scale
The ALRT Diabetes Solution is an enterprise-scale product that allows healthcare systems to implement best practices for diabetes care on large populations of patients - saving lives and money.
The ALRT Diabetes Management System
Details of the patent pending diabetes management system featuring Predictive A1C values and Insulin Dose Adjustment
ALRT Adding International Reference Dosing to Insulin Dose Adjustment (IDA) Feature for International Market Expansion
Product development underway to add reference doses based on International Diabetes Federation, Australia, Canada, New Zealand and UK Guidelines
FDA Grants ALRT Clearance for Insulin Dose Adjustment (IDA) Feature
IDA is designed to ensure that patients get an effective and timely insulin dose(s) based on accurate data about their specific needs
ALRT System Significantly Lowers A1C Levels in Type 2 Diabetes Patients in Real World Pilot Program
A 10-month pilot of the ALRT remote monitoring system for diabetes by the Kansas City Metropolitan Physician Association (KCMPA) has found significant improvement in glycemic control for those patients who used the system compared to those who dropped out of the pilot.
ALR Technologies Seeks FDA Approval For Insulin Dose Adjustment Feature for Better Diabetes Management
A first-in-class technology, the Insulin Dose Adjustment Consultation (IDAC) feature from ALRT uses an algorithm -- based on the guidelines of the American Association of Clinical Endocrinologists (AACE) -- to advise doctors instantly on the proper dose of insulin for each patient. The algorithm takes into account the current insulin dosage, the patient’s height and weight, and a review of blood glucose data from the patient’s glucose meter to efficiently deliver accurate dosing recommendations. With FDA 510(k) clearance, IDAC will become an important addition to the Health-e-Connect remote diabetes care management system.
ALRT System May Help Providers Meet Chronic Care Management Reimbursement Requirements
An analysis from Avalere Health LLC, commissioned by ALRT, follows the Centers for Medicare & Medicaid Services’ (CMS) establishment of a new reimbursement code for non-face-to-face chronic care management (CCM) with a payment rate of $42.60 per patient per month. This new payment is available to providers as of January 1, 2015, but only if they meet CMS’ extensive and complex requirements, according to Avalere. The ALRT system is designed to enable medical practices to meet these requirements while helping improve outcomes for patients with diabetes.
CMS To Reimburse Physicians for Remote Chronic Care Starting January 1, 2015
ALRT’s Product Offering for Diabetes Management Will Allow Physician Groups to Access the New Reimbursement
ALR Technologies Advocates For Sensible Medicare Reimbursement of Continuous Glucose Monitoring (CGM) for Diabetes Patients
Internet Monitoring More Cost Effective than Continuous Glucose Monitoring (CGM) for Most Medicare Patients Says ALRT President Bill Smith
ALR Technologies Letter to Center for Medicare and Medicaid Services
ALR Technologies Begins Enrolling Patients in Kansas City
Partnership with KCMPA Marks First Large-Scale Commercial Deployment of the Health-e-Connect Remote Disease Management System
Forbes Says ALRT Among the Startups and Small Companies to Benefit From CMS Rule
After July ended with what I called a “big week for telemedicine and telehealth,” August started with at least one telehealth company — maybe more “digital health,” but let’s not split hairs here — getting some national TV coverage to discuss an important development in the field.
The Kansas City Metropolitan Physician Association and ALR Technologies Announce Diabetes Management Partnership
Collaboration With Pioneering Accountable Care Organization Marks First Commercial Deployment of the Health-e-Connect System
Proposed CMS Rules Present ALRT with Significant New Market Opportunities for Remote Monitoring of Patients with Chronic Conditions
Beginning next year, primary care physicians and others could begin billing separately for chronic care management (CCM) services if the Physician Fee Schedule (PFS) proposed by the Centers for CMS is adopted. These changes in the Medicare fee-for-service program have the potential to create generous new incentives for telemedicine companies that specialize in remote monitoring of patients with chronic conditions.
ALR Technologies' Letter to Shareholders
First, thank you for your continuing support for our company. It is an exciting time at ALRT and, as we have done in the past, I will continue to send out occasional updates on our progress with the intention of keeping you and the general public informed about recent developments and the prospects for our company's success.
ALR Technologies Announces Electronic Insulin Dosing Consultations by Endocrinologists
New Feature of Health-e-Connect System Will Encourage Widespread Adoption of Intensive Blood Glucose Management
ALR Technologies Announces Mac OS Compatibility for the Health-e-Connect System
Mac compatibility represents a significant opportunity for many Mac-using patients with diabetes, as monitoring software for some of the major glucose meters brands is compatible only with Windows-based computers. The ALRT Mac-friendly software will now be an option for patients with the following brands of meter: LifeScan, Nipro, Bayer, Abbott and Roche.
ALR Technologies Letter to Shareholders
I wanted to take a moment to update you on the recent progress of ALR Technologies and to lay out our strategy for the commercialization of our services and our technology.
ALR Technologies Appoints Dr. Kent Stoneking as Director of Diabetes Care Facilitation
ALR Technologies, a medical device company providing remote monitoring and care facilitation for patients with chronic diseases, today announced that Kent Stoneking, Pharm. D., CDE, has been appointed Director, Diabetes Care Facilitation, effective February 1, 2013\. Dr. Stoneking will oversee the hiring, training, and ongoing activities of ALRT’s Diabetes Care Facilitators (DCFs) who will monitor the data of diabetes patients and coordinate care with clinicians, caregivers, health plans and others.